Colgate-Palmolive's (CL) Q4 organic sales growth was weaker than expected, but Morgan Stanley remains optimistic about its long-term trajectory, expecting the company to outpace most peers in organic sales growth.
The firm noted in a Monday note that Colgate-Palmolive's 2025 EPS guidance was better than expected, driven by pricing strategies and past reinvestment. However, cost pressures and foreign exchange risks make the lower end of guidance seem more achievable.
"We are more bullish than most investors we spoke with and believe that Colgate-Palmolive will be a 4% organic sales growth company going forward, supported by pricing power and market share gains," Morgan Stanley added.
The firm added that Colgate-Palmolive's global toothpaste market share dipped slightly due to foreign exchange-driven mix effects, while Hill's Pet Nutrition contributed to overall growth, despite European weakness.
Morgan Stanley reduced its price target of Colgate-Palmolive's stock to $104 from $111 and has an overweight rating.
Price: 86.33, Change: -0.37, Percent Change: -0.43
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。